Cidofovir

From Wikipedia, the free encyclopedia

Cidofovir
Systematic (IUPAC) name
[1-(4-amino-2-oxo-pyrimidin-1-yl)- 3-hydroxy-propan-2-yl] oxymethylphosphonic acid
Identifiers
CAS number 113852-37-2
ATC code J05AB12
PubChem 60613
DrugBank APRD00148
Chemical data
Formula C8H14N3O6P 
Mol. mass 279.187 g/mol
Physical data
Melt. point 260 °C (500 °F)
Spec. rot -97.3
Pharmacokinetic data
Bioavailability  ?
Protein binding 6%
Metabolism  ?
Half life 2.4 to 3.2 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis.

Cidofovir demonstrated a statistically significant effect in delaying the progression of CMV retinitis lesions in newly diagnosed patients, as well as in previously treated patients who had failed other therapies. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. The major side effect of cidofovir is that it can be nephrotoxic.

  • Cidofovir has also shown efficacy in the treatment of acyclovir resistant herpes
  • Cidofovir might have anti-smallpox efficacy and might be used on a limited basis in the event of a bioterror incident involving smallpox cases.

Cidofovir was developed by Gilead Sciences and is marketed with the brand name Vistide® by Gilead in the USA, and by Pfizer elsewhere.


In other languages